Sagimet Biosciences, Inc. (SGMT)
10.80
-0.29
(-2.61%)
USD |
NASDAQ |
Sep 21, 16:00
10.80
0.00 (0.00%)
After-Hours: 20:00
Sagimet Biosciences Enterprise Value : 446.98M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 446.98M |
| September 17, 2026 | 451.93M |
| September 16, 2026 | 408.06M |
| September 15, 2026 | 408.06M |
| September 14, 2026 | 434.01M |
| September 11, 2026 | 434.01M |
| September 10, 2026 | 445.13M |
| September 09, 2026 | 432.77M |
| September 08, 2026 | 423.51M |
| September 04, 2026 | 437.72M |
| September 03, 2026 | 436.48M |
| September 02, 2026 | 440.81M |
| September 01, 2026 | 410.53M |
| August 31, 2026 | 395.70M |
| August 28, 2026 | 413.62M |
| August 27, 2026 | 425.98M |
| August 26, 2026 | 432.77M |
| August 25, 2026 | 397.56M |
| August 24, 2026 | 392.62M |
| August 21, 2026 | 395.09M |
| August 20, 2026 | 390.76M |
| August 19, 2026 | 415.48M |
| August 18, 2026 | 415.48M |
| August 17, 2026 | 406.21M |
| August 14, 2026 | 413.62M |
| Date | Value |
|---|---|
| August 13, 2026 | 335.16M |
| August 12, 2026 | 341.95M |
| August 11, 2026 | 349.99M |
| August 10, 2026 | 353.07M |
| August 07, 2026 | 321.57M |
| August 06, 2026 | 301.79M |
| August 05, 2026 | 295.62M |
| August 04, 2026 | 255.46M |
| August 03, 2026 | 203.56M |
| July 31, 2026 | 201.09M |
| July 30, 2026 | 213.44M |
| July 29, 2026 | 196.76M |
| July 28, 2026 | 210.97M |
| July 27, 2026 | 222.09M |
| July 24, 2026 | 198.62M |
| July 23, 2026 | 194.91M |
| July 22, 2026 | 197.38M |
| July 21, 2026 | 198.62M |
| July 20, 2026 | 204.18M |
| July 17, 2026 | 244.95M |
| July 16, 2026 | 234.45M |
| July 15, 2026 | 255.46M |
| July 14, 2026 | 240.94M |
| July 13, 2026 | 203.56M |
| July 10, 2026 | 217.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.980B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.95M |
| Total Expenses (Quarterly) | 13.95M |
| EPS Diluted (Quarterly) | -0.2627 |
| Earnings Yield | -11.87% |
| Normalized Earnings Yield | -11.87 |